63 results about "Dilated cardiomyopathy" patented technology

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The application provides a method for constructing an animal model of dilated cardiomyopathy and application, belongs to the technical field of biological medicine and animal genetic model construction, provides a new zebrafish model of dilated cardiomyopathy, is constructed by specifically overexpressing a truncated dnajb6b gene long isoform fragment in zebrafish myocardial cells, the nucleotide sequence of the gene fragment is shown as SEQ ID NO. 1, and the method for constructing the zebrafish model of dilated cardiomyopathy and application are provided, and it is further found that 4-phenylbutyric acid is applied to the preparation of a drug for treating dilated cardiomyopathy.

The invention provides an LMNA mutant gene and application thereof, and belongs to the technical field of biomedicine. The nucleotide sequence of the human LMNA mutant gene is as shown in SEQ ID NO. 1. The LMNA mutant gene can be used for screening dilated cardiomyopathy and atrioventricular block and constructing a non-human animal model of the dilated cardiomyopathy and the atrioventricular block, and is beneficial to exploring pathophysiological processes of the dilated cardiomyopathy and the atrioventricular block and exploring therapeutic targets and drugs of the dilated cardiomyopathy and the atrioventricular block.

This application relates to the biomedical field and discloses a combination of biomarkers based on mitochondrial oxidative stress for the auxiliary diagnosis of dilated cardiomyopathy and its application. The biomarker combination includes the TARS2, NOX4, and SNCA genes. This biomarker combination can be used to prepare auxiliary diagnostic kits for dilated cardiomyopathy. By detecting the expression levels of each gene in the biomarker combination, the auxiliary diagnosis of dilated cardiomyopathy can be achieved efficiently and accurately. Compared with traditional diagnostic methods, this application, based on the characteristics of mitochondrial oxidative stress-related genes, has higher diagnostic accuracy and better applicability.

The invention discloses a processing method and device based on a heart three-dimensional image, equipment and a medium. The method comprises the following steps: acquiring a heart three-dimensional image and a chamber segmentation result to obtain a left ventricular heart cavity and a cardiac muscle; according to the inner diameter and the outer diameter of the myocardial, constructing a three-dimensional inner diameter curved surface and generating myocardial wall thickness mapping; determining a pre-trained classification model and constructing two-channel input of the classification model; inputting the curved surface and the mapping into a first channel of a model, and combining whole heart segmentation or original image data of a second channel; and processing dual-channel input through the model, and outputting a cardiomyopathy classification result. According to the method, a complete spatial form is reserved through the three-dimensional inner diameter curved surface and wall thickness mapping, and precise and robust classification of various cardiomyopathy such as hypertrophic cardiomyopathy and dilated cardiomyopathy is realized by combining dual-channel feature fusion and interactive calibration of a space guidance mask; the problems of efficiently and accurately extracting features from a complex three-dimensional heart image and automatically identifying diseases are solved.

The invention provides a dilated cardiomyopathy child death risk prediction method, system and device, and relates to the technical field of medical prediction models.The method comprises the steps that clinical data of a target dilated cardiomyopathy child patient are obtained and input into a pre-constructed nomogram prediction model, and death risk prediction results of the target dilated cardiomyopathy child patient at multiple time points in the future are output; the nomogram prediction model is constructed through independent prediction factors, the amino-terminal brain natriuretic peptide precursor level, the gender and the digoxin use condition which are determined through single-factor and multi-factor Cox regression analysis. According to the method, the nomogram prediction model is constructed by integrating the key clinical variables, accurate prediction and individualized treatment guidance of the dilated cardiomyopathy death risk of children are achieved, and the accuracy of clinical decision and the prognosis management effect are effectively improved.

The application provides an application of (R)-8-hydroxy-3,5,7-trimethylisochroman-1-one in preparation of an anti-dilated cardiomyopathy drug, belongs to the technical field of anti-dilated cardiomyopathy drugs, and discloses that the compound (R)-8-hydroxy-3,5,7-trimethylisochroman-1-one has an anti-dilated cardiomyopathy effect for the first time, and provides an experimental basis and a theoretical basis for development of a new drug for preventing or treating dilated cardiomyopathy.

Provided herein are compositions and methods for treating or preventing dilated cardiomyopathy (DCM) in a subject in need thereof, for example, through correcting one or more point mutations in the RBM20 locus using CRISPR-associated base editing. TIFF2025538153000011.tif56128

The application discloses a traditional Chinese medicine composition for treating dilated cardiomyopathy, relates to the field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for improving ventricular remodeling of a dilated cardiomyopathy patient, which is prepared from the following traditional Chinese medicines in parts by weight: radix astragali 60-90 parts, semen platycladi 15-30 parts, cortex mori 15-30 parts, ramulus cinnamomi 10-15 parts, zingiberis rhizoma siccum 10-15 parts, curcuma zedoaria 10-20 parts, cinnamomum cassia 6-10 parts and euonymus alatus 10-15 parts. The application has remarkable advantages in improving heart failure symptoms of the DCM patient, reversing ventricular remodeling, improving exercise tolerance, controlling arrhythmia and improving long-term prognosis of the patient.

The application belongs to the field of genetic engineering, and particularly relates to a polynucleotide construct capable of expressing LMNA and application thereof in preventing and treating DCM. The synthetic intron in the application comprises: I) a nucleotide sequence as shown in SEQ ID No. 8, II) a nucleotide sequence having at least one mutation in the 1-8th position of the sequence shown in SEQ ID No. 8, or a nucleotide sequence having at least 90% homology with the sequence shown in I) or II). By using the synthetic intron in the application, two proteins can be simultaneously expressed through alternative splicing, and the ratio of the two proteins or the expression of a single protein can be regulated through mutation of the splicing signal. Compared with the existing gene therapy method for dilated cardiomyopathy caused by LMNA mutation, the expression vector for simultaneously expressing Lamin A and Lamin C proteins in the application has stronger rescue effect.

This invention discloses a high-throughput screening method and system for KLHL24 ubiquitin ligase inhibitors. The method exhibits high stability and reproducibility, facilitating the efficient screening of KLHL24 ubiquitin ligase inhibitors and the development of related drugs. Based on the aforementioned method, this invention has screened several KLHL24 ubiquitin ligase inhibitors, which can be effectively used to treat KLHL24-related diseases, particularly those caused by KLHL24 mutations, such as hereditary epidermolysis bullosa, dilated cardiomyopathy, alopecia, and atrophic scarring, showing excellent application prospects. Given the function of KLHL24 in skin and hair regeneration, this inhibitor also shows good application potential in maintaining normal hair growth.

The invention provides a heart transplantation nutrition prognosis analysis system for a patient with dilated cardiomyopathy, three factors including prealbumin (PA), total bile acid (TBA) and NRS2002 score are incorporated into the analysis system, a corresponding algorithm is provided, and based on the algorithm, the optimal cutoff value of an undesirable outcome is predicted to be 0.121, the sensitivity is 72.9%, the specificity is 92.9%, and the area under a ROC curve (AUC) is 0.885 (95% CI: 0.802-0.967); when the absolute error of a calibration curve is 0.049, the HL goodness of fit test is equal to 6.134 (P is equal to 0.632 gt, 0.05), the net income threshold probability of DCA is 0.04-0.94, and the threshold probability of CIC is greater than 0.50, the prediction is highly consistent with the actual outcome. Meanwhile, the AUC value of the algorithm is obviously larger than that of other existing prediction methods, the algorithm can serve as a reliable tool for evaluating the postoperative adverse outcome risk of the patient in clinical practice, an important reference basis is provided for optimizing the individualized treatment strategy of the patient to be transplanted and perfecting the organ distribution scheme, and the accuracy and rationality of heart transplantation diagnosis and treatment can be improved.

The present invention provides novel polymorphs of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide (I-491) that are useful for the treatment of cardiac disorders including systolic dysfunction, dilated cardiomyopathy (DCM), heart failure with reserved ejection fraction (HFrEF), and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the polymorphs is described, as well as methods for treating systolic dysfunction, DCM, HFrEF, and other forms of heart disease.

The application belongs to the technical field of molecular diagnosis, and particularly relates to extracellular vesicle lncRNA as a molecular marker for diagnosing heart failure combined with dilated cardiomyopathy. The molecular marker is NR_045681, and the specific nucleic acid sequence of the extracellular vesicle lncRNA is shown in SEQ ID NO. 5. The technical scheme provided by the application effectively improves the detection accuracy of heart failure combined with dilated cardiomyopathy. The P value of the combination of the molecular marker is less than 0.05, the |log fold change (FC)| is greater than 1, and the molecular marker has obvious differential expression relative to a healthy control group.

This invention discloses an intelligent terminal and early warning method for home management of dilated cardiomyopathy (DCM) in children, integrating multi-parameter monitoring, belonging to the field of intelligent health management technology. The method includes the following steps: establishing an electromagnetic event timeline in the home health monitoring environment; synchronously collecting and correlating electrocardiogram (ECG), blood oxygen saturation, and body movement signals according to a unified time reference to form an intelligent early warning baseline and generate a time anchor. This invention achieves synchronous correlation between multi-source physiological signals and interference by establishing an electromagnetic event timeline and time anchor, and dynamically rearranges sampling time to maintain signal continuity. Through a rhythmic breathing-type time control table and a dynamic interference isolation mechanism, the sampling rhythm is inversely coordinated with electromagnetic events, effectively improving the stability and accuracy of heart rhythm analysis and achieving intelligent early warning for dilated cardiomyopathy in children.

A compound of Formula (I) is provided: (I) Salts and crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, inflammatory and fibrotic diseases, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.

The present disclosure provides novel methods of chemical synthesis useful for the manufacturing of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide (referred to herein as a compound of Formula ( I )), also known as danicamtiv, and a polymorphic form thereof. Danicamtiv is useful for the treatment of cardiac disorders including systolic dysfunction, dilated cardiomyopathy (DCM), heart failure with reserved ejection fraction (HFrEF), and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve.

The application discloses application of SFRP3 in prevention and treatment of dilated cardiomyopathy, and belongs to the technical field of biological medicine. The application down-regulates SFRP3 expression in myocardial cells by means of gene interference, RNA interference technology, antibody or small molecule inhibitor, etc. to treat dilated cardiomyopathy, realizes the purposes of improving heart function, reducing cardiac dilatation, improving myocardial fibrosis and effectively promoting myocardial repair, and provides a more effective and low-side-effect treatment method for treatment of dilated cardiomyopathy. The treatment idea provided by the application can not only relieve symptoms of dilated cardiomyopathy, but also regulate physiological processes of heart cells at a molecular level, and provides a new idea for clinical treatment of dilated cardiomyopathy.

The present disclosure relates to α1A-AR agonist compounds, pharmaceutical compositions, and methods of using the compounds and composition for treating conditions associated with right ventricular failure. In addition the disclosed compounds and compositions can be used for treating cardiomyopathies, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, restrictive cardiomyopathy, left ventricular noncompaction, right ventricular failure (RVF), and takotsubo cardiomyopathy. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention provides an application of (R)-8-hydroxy-3, 5, 7-trimellisochroman-1-one in preparation of drugs for resisting dilated cardiomyopathy, and belongs to the technical field of drugs for resisting dilated cardiomyopathy. It is found for the first time that the compound (R)-8-hydroxy-3, 5, 7-trimellisochroman-1-one has the effect of resisting dilated cardiomyopathy, and the application of (R)-8-hydroxy-3, 5, 7-trimellisochroman-1-one in preparation of drugs for resisting dilated cardiomyopathy in preparation of drugs for resisting dilated cardiomyopathy in preparation of drugs for resisting dilated cardiomyopathy in preparation of drugs for resisting dilated cardiomyopathy in preparation of drugs for resisting dilated cardiomyopathy. The invention provides experimental basis and theoretical basis for research and development of new drugs for preventing or treating dilated cardiomyopathy.

This invention discloses a targeted drug delivery system for treating dilated cardiomyopathy in children, relating to the field of targeted drug delivery technology. It includes a time baseline construction module, a heart rate mutation prediction module, a drug release rhythm control module, a phase-locked control module, and an energy distribution control module. The time baseline construction module establishes a unified time baseline during targeted drug delivery, integrating heart rate, blood flow velocity, and blood pressure signals in the same temporal order to generate a time reference baseline reflecting cardiac rhythm changes. This invention achieves time synchronization by establishing a unified time baseline and combining heart rate, blood flow, and blood pressure signals, ensuring that the drug release rhythm remains consistent with cardiac changes. Pre-emptive regulation is achieved through prediction windows and buffer indexes to eliminate feedback oscillations. The combination of a rhythm control table, phase-locked path, and energy distribution chain coordinates energy output with flow rate, maintaining stable and accurate drug delivery.

The invention discloses a yang-warming, qi-tonifying and blood-activating preparation and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations. The yang-warming, qi-tonifying and blood-activating preparation is prepared from the following traditional Chinese medicinal materials in specific parts by weight: astragalus membranaceus, codonopsis pilosula, cassia twig, poria cocos, semen lepidii, rhizoma atractylodis macrocephalae, radix curcumae, salvia miltiorrhiza, radix ophiopogonis, rhodiola rosea, honey-fried licorice root and the like, and auxiliary materials including stabilizer beta-cyclodextrin, erythritol and geniposidic acid. The preparation process comprises the steps of pretreatment of medicinal materials, extraction and inclusion of volatile oil, water extraction, concentration and mixing, mixing and granulation of auxiliary materials, total mixing, sub-packaging and the like, and effective components are effectively reserved and the stability of the preparation is improved by means of step-by-step extraction, an inclusion technology, low-temperature drying and the like. The yang-warming, qi-tonifying and blood-activating preparation has the effects of warming yang, tonifying qi, activating blood and inducing diuresis, can be used for preparing a medicine for treating dilated cardiomyopathy, can remarkably improve the curative effect and improve the symptoms such as palpitation, shortness of breath and edema of a patient when being combined with enalapril, has the total clinical effective rate of 93.3%, and has good stability and clinical popularization value.

The invention relates to the field of medicine, in particular to a biomarker for diagnosis and prognosis evaluation of ventricular arrhythmia of a patient with dilated cardiomyopathy (DCM) and application of the biomarker. Matrix metalloproteinase-9 (MMP-9), 5-hydroxytryptamine (5-HT), noradrenaline (NE) and acetylcholine (ACh) are screened to serve as a biomarker combination, and by measuring the levels of MMP-9, 5-HT, NE and ACh in plasma, whether a DCM patient is accompanied with ventricular arrhythmia or not can be effectively recognized, the severity of the condition of the patient is evaluated, and the prognosis risk of the patient is predicted. The synergistic effect of MMP-9, 5-HT, NE and ACh can complement the defects of a single index, the diagnosis efficiency is improved, particularly, high specificity is achieved for ventricular arrhythmia, and an important basis is provided for risk stratification and individualized treatment of DCM patients.

The present disclosure provides compositions and methods for inducing a dilated cardiomyopathy (DCM) phenotype in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The present disclosure also provides methods for identifying a personalized risk stratification paradigm for DCM patients that predicted individual-level risk of mechanical dysfunction and significant arrhythmia using the functional phenotype of patient-specific iPSC-CMs.

Methods for the treatment and prevention of laminopathies and diseases characterised by hyperlipidemia through LING complex inhibition are disclosed. In particular, LING complex disruption by expression of dominant-negative LING complex proteins alleviates pathophysiology in Lmna mutation-associated muscular dystrophy, progeria, and dilated cardiomyopathy. In addition, LING complex disruption by expression of dominant-negative LING complex proteins also alleviates pathophysiology in mouse models of atherosclerosis and familial hypercholesterolemia.

The invention discloses a preparation method of a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating hypertrophic cardiomyopathy, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the traditional Chinese medicine for treating dilated cardiomyopathy, atherosclerotic plaque, myocardial fibrosis, ventricular remodeling, senile cardiac metabolic disorder, hypertrophic cardiomyopathy, hypertrophic cardiomyopathy and hypertrophic cardiomyopathy aiming at the defects of the prior art in preparation of medicines for preventing and treating hypertrophic cardiomyopathy. The invention also discloses application of the traditional Chinese medicine composition in preparation of medicines for treating hypertrophic cardiomyopathy, wherein the traditional Chinese medicine composition has the effects of improving cardiac degeneration of mice with myocardial hypertrophy induced by blood constriction. According to the key point of the technical scheme, the invention provides the application of the traditional Chinese medicine composition in preparing the medicine for preventing and treating hypertrophic cardiomyopathy. The traditional Chinese medicine composition comprises the following raw materials: American ginseng, ginseng, astragalus membranaceus, spina date seeds, salvia miltiorrhiza, pseudo-ginseng, fingered citron and mangnolia officinalis.

The invention provides application of FAD in preparation of a medicine for treating dilated cardiomyopathy. According to the application disclosed by the invention, under the condition of lambda A / C deficiency, exogenous supplement FAD is found to have a recovery effect on Lmna- / -mouse myocardial cell energy metabolism and have a reversal effect on Lmna- / -mouse myocardial mitochondrial injury and DCM phenotype. The application of FAD is expanded to the field of cardiovascular diseases, especially for LMNA-related DCM lacking effective treatment means at present, the treatment blank in the field is filled, and important originality and pioneering are achieved. On the basis of FAD, a new treatment strategy of related DCM is established, and the method has a good market application prospect.

The invention discloses a humanized monoclonal antibody of a beta1-adrenergic receptor as well as a kit and application of the humanized monoclonal antibody. The amino acid sequence of the humanized monoclonal antibody of the beta1-adrenergic receptor is as shown in SEQ ID No.1. The invention further discloses a preparation method of the humanized monoclonal antibody of the beta1-adrenergic receptor. According to the distribution condition of myocardial antigenic determinants, polypeptides of natural antigenic determinants are designed and synthesized to immunize animals to prepare monoclonal antibodies and carry out humanized expression, so that the antibody detection kit is prepared. The kit can be used for auxiliary diagnosis of autoimmune response activation and prognosis judgment of patients with viral myocarditis and dilated cardiomyopathy, and auxiliary establishment of a patient treatment scheme.